Mannkind (MNKD) Income from Continuing Operations (2010 - 2026)
Mannkind (MNKD) reported Income from Continuing Operations of 16619000.0 for Q1 2026, down 226.3% year-over-year from 13158000.0 in Q1 2025, and up 20.47% quarter-over-quarter from 20897000.0 in Q4 2025.
Mannkind (MNKD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Income from Continuing Operations data on file, last reported at 16619000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 16619000.0, down 226.3% year-over-year; the trailing twelve-month figure through Mar 2026 was 28867000.0 (down 195.8% YoY), and the FY2025 annual result was 914000.0, down 96.69% from the prior year.
- Income from Continuing Operations climbed to 16619000.0 in Q1 2026 per MNKD's latest filing, from 20897000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 13158000.0 in Q1 2025 and troughed at 29023000.0 in Q2 2022.
- A 5-year average of 5143352.94 and a median of 1991000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 571.12% in 2024, then sank 381.82% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 17947000.0 in 2022, then jumped by 107.84% to 1407000.0 in 2023, then soared by 427.01% to 7415000.0 in 2024, then slumped by 381.82% to 20897000.0 in 2025, then gained by 20.47% to 16619000.0 in 2026.
- Business Quant data shows MNKD's Income from Continuing Operations at 16619000.0 in Q1 2026, 20897000.0 in Q4 2025, and 7981000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | -16.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.62 Mn |
| Dec 31, 2025 | -20.90 Mn |
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 668,000.00 |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 7.42 Mn |
| Sep 30, 2024 | 11.55 Mn |
| Jun 30, 2024 | -1.99 Mn |
| Mar 31, 2024 | 10.63 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | -5.27 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -17.95 Mn |
| Sep 30, 2022 | -14.43 Mn |
| Jun 30, 2022 | -29.02 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -28.06 Mn |
| Sep 30, 2021 | -4.43 Mn |
| Jun 30, 2021 | -35.52 Mn |